The Latest Cardiac and Vascular News
DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International, Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common […]
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) — Avinger (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from […]
by Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) A new study published in the Journal of the American Heart Association shows that AMIs following a percutaneous coronary intervention (PCI) is twice as likely to originate from untreated lesions versus previous stented lesions. Interesting since this information seems to differ from previous studies such as PROSPECT […]
IRVINE, Calif., Jan. 18, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended December 31, 2017 after the market closes on Thursday, February 1, 2018, and will host a conference call at 5:00 p.m. […]
AUSTIN, Texas, Jan. 18, 2018 /PRNewswire/ — On Nov. 14, 2017, Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center became the first hospital in Texas—and among the first in the nation—to use the new smartphone compatible Confirm Rx™ Insertable Cardiac Monitor (ICM), the world’s first and only smartphone compatible ICM designed to help physicians […]
ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced two new partnerships broadening the company’s product portfolio. CSI is now the exclusive U.S. distributor of OrbusNeich balloon products. Additionally, the […]
FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, […]
SAN ANTONIO, Jan. 18, 2018 /PRNewswire/ — Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access, today announced the enrollment of its first patients in the SAVE-US (Surfacer® System to Facilitate Access in VEnous Occlusions – United States) pivotal trial. The SAVE-US clinical trial is a pre-market […]
VANCOUVER, Jan. 18, 2018 /PRNewswire/ – Neovasc Inc. today reported its Neovasc Reducer™ (“Reducer”) was featured in a “live case” broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany. The successful live case was performed by Dr. Spyrantis and Professor Banai in the Sana-Klinikum Lichtenberg. “The […]
Patient death prompts safety warning by FDA. Zoll LifeVest 4000 Wearable Cardioverter Defibrillator: FDA Safety Communication – Potential Lack of Treatment (Shock) Delivery Due to Device Failure by FDA.gov ISSUE: FDA is providing information and recommendations regarding the Zoll LifeVest 4000 due to concerns that the device may fail to […]
